Composition for controlling growth of bacteria in the intestinal tract and use thereof
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective materials for controlling the growth of specific bacteria in the intestinal tract, including Faecalibacterium, Akkermansia, Blautia, Subdoligranulum, Bilophila, and Sutterella, which are associated with various diseases.
Innovation Solution
A composition containing human milk oligosaccharides and their constituent sugars, such as sialic acid, N-acetylneuraminic acid, 3′-sialyllactose, and 6′-sialyllactose, is used to promote or suppress the growth of these bacteria in the intestinal microbiota.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional materials are used to control bacterial growth in the intestinal tract, then some bacterial control effect is achieved, but the control is insufficient for specific bacteria associated with diseases
Solution Approach 1:
The patent changes the chemical parameter of the prebiotic substance by specifically selecting sialic acid-containing oligosaccharides (such as sialyllactose) from the broad category of oligosaccharides. This parameter change enables selective promotion of beneficial bacteria (Faecalibacterium, Akkermansia, Blautia, Subdoligranulum) while suppressing harmful bacteria (Bilophila, Sutterella), achieving both reliability and specificity in bacterial growth control
Solution Approach 2:
The patent applies local quality by targeting specific bacterial genera with different responses to sialic acid-containing oligosaccharides. Beneficial bacteria located in the intestinal tract receive selective promotion through their specific ability to utilize sialic acid, while harmful bacteria are suppressed, creating differentiated local effects within the intestinal microbiota
2Adaptability or versatility
If broad-spectrum antibacterial agents are used, then general bacterial growth is controlled, but specific disease-associated bacteria are not effectively targeted
Solution Approach 1:
The patent introduces sialic acid-containing oligosaccharides as an intermediary substance that indirectly controls bacterial growth. Instead of using direct antibacterial agents, the oligosaccharides serve as a mediator that selectively nourishes beneficial bacteria which then compete with and suppress harmful bacteria, achieving specific targeting without broad-spectrum direct action
Solution Approach 2:
The patent converts the concept of bacterial competition from a harmful effect into a beneficial mechanism. By promoting beneficial bacteria through sialic acid-containing oligosaccharides, the natural competitive exclusion mechanism is harnessed to suppress harmful bacteria, turning the potentially harmful presence of multiple bacterial species into a beneficial self-regulating system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively controls the growth of targeted bacteria, potentially treating conditions like irritable bowel syndrome, inflammatory bowel disease, obesity, diabetes, and metabolic disorders by modulating the intestinal microbiota.
Implementation Method 1
A composition containing human milk oligosaccharides and their constituent sugars, such as sialic acid, N-acetylneuraminic acid, 3'-sialyllactose, and 6'-sialyllactose, is used to promote or suppress the growth of these bacteria in the intestinal microbiota
Data Source
AI summary
A means for controlling growth of any bacteria selected from the group consisting of bacteria of the genus Faecalibacterium, bacteria of the genus Akkermansia, bacteria of the genus Blautia, bacteria of the genus Subdoligranulum, bacteria of the genus Bilophila, and bacteria of the genus Sutterella in the intestinal tract is provided. An object of the present invention is to provide a novel material that can control growth of bacteria of the genus Faecalibacterium. There is provided a composition for controlling growth of target bacteria in intestinal bacterial microbiota, which contains any selected from the group consisting of a human milk oligosaccharide and a constituent sugar of a human milk oligosaccharide.